JR White - Clinical Diabetes, 2008 - Am Diabetes Assoc Adecade and a half ago, the choice of an oral antihyperglycemic agent for any
particular patient was in some ways a debate of nuance. Sulfonylureas (SUs) were
the only class available, and providers were left to sift though ... Cited by 3 - Related articles - BL Direct - All 2 versions
RG Moses - Clinical Therapeutics, 2008 - Elsevier Results: In the original analysis, which employed an HbA 1c target of
<7.1%,59%of patients treated with metformin plus repaglinide achieved their
glycemic target, compared with 20%of patients treated with metformin or ... Cited by 2 - Related articles - All 2 versions
X Zhao, YM Cui, Y Zhou, HL Zhang, KP Yeo, H … - International journal of clinical pharmacology and …, 2008 - ncbi.nlm.nih.gov OBJECTIVES: Exenatide is an adjunctive treatment for Type 2 diabetes. This was
the first study to evaluate the pharmacokinetics, safety and tolerability of
therapeutic doses (5 microg and 10 microg) of exenatide after single and ... Cited by 2 - Related articles - All 2 versions
FM Couto, AH Minn, CA Pise-Masison, M … - Metabolism-Clinical and Experimental, 2007 - biostat.wisc.edu Page 1. Exenatide blocks JAK1-STAT1 in pancreatic beta cells Francesca M. Couto
a , Alexandra H. Minn a , Cynthia A. Pise-Masison b , Mike Radonovich b , ... Cited by 2 - Related articles - View as HTML - All 16 versions
BP Childs, NC Kesty, E Klein, R Rubin, A Wick - Diabetes Spectrum, 2007 - Am Diabetes Assoc Patient concerns extend beyond the threat of diabetes-related complications.
Daily life is burdened by high and low glucose concentrations, which require
vigilant daily monitoring, and by the fear of hypoglycemia. Management of ... Cited by 2 - Related articles - BL Direct - All 2 versions
H Fuder, P Kleist, M Birkel, A Ehrlich, S … - European journal of clinical pharmacology, 1997 - Springer Abstract Objective: Voglibose is a new and potent in- hibitor of a-glucosidases
and is used for the treatment of diabetes mellitus. Since voglibose increases
gastrointes- tinal motility and could thus a ect absorption of con- ... Cited by 2 - Related articles - BL Direct - All 5 versions
J El-Hilaly, A Tahraoui, ZH Israili, BÂ Lyoussi - Pak J Pharm Sci, 2007 - pjps.pk ABSTRACT The hypoglycemic and hypolipidemic effect of continuous intravenous
infusion of a lyophilised aqueous extract of the whole plant Ajuga iva (L.)
Schreber (Labiatae) (AI-extract) was investigated in anesthetized normal ... Cited by 2 - Related articles - View as HTML - All 5 versions
L Brunetti, G Orlando, L Recinella, S Leone, C … - Peptides, 2008 - Elsevier Glucagon-like peptide 1 (7–36) amide (GLP-1) and exendin-4 are
gastrointestinal hormones as well as neuropeptides involved in glucose
homeostasis and feeding regulation, both peripherally and at the central ... Cited by 2 - Related articles - All 2 versions
PA Kothare, H Linnebjerg, Y Isaka, K Uenaka … - The Journal of Clinical Pharmacology, 2008 - jcp.sagepub.com In this single-blind, parallel, placebo-controlled study, the pharmacokinetics,
pharmacodynamics, tolerability, and safety of subcutaneous exenatide were
evaluated in 40 Japanese patients with type 2 diabetes. Patients were ... Cited by 2 - Related articles - All 4 versions
